CINCINNATI and ANAHEIM, Calif., Nov. 14, 2016 /PRNewswire/ -- Schulman IRB, the industry-leading central IRB in customer service and technology, is pleased to announce its Central Oncology Review (COR) division is open for business.
COR, which is led by Michele Russell-Einhorn, VP of Oncology, and Judith Carrithers, Director of Oncology Services, provides collaborative, flexible IRB review services for oncology research organizations seeking a more advanced level of partnership and service integration from a central IRB. This service represents Schulman's response to requests from institutional research centers.
"We are intimately familiar with the unique requirements of cancer research centers and institutional IRBs," said Russell-Einhorn. "COR combines our deep understanding of this environment with Schulman IRB's best-in-class customer service and compliance record, providing cancer research centers and their IRBs with unparalleled transparency and collaboration throughout the review process."
In addition to the leadership of Russell-Einhorn and Carrithers, COR features an IRB roster of oncology industry leaders, academics and distinguished scientists, each with a background in managing specialized oncology research. COR will assist research organizations in meeting the challenges of regulatory changes like NIH's single IRB policy and HHS' proposed changes to the "Common Rule," which will require multicenter research studies to be overseen by a central IRB.
COR clients will interact with the IRB via Schulman's intuitive suite of eTools, which offer real-time reporting capabilities and can be integrated with institutional technology platforms.
About Central Oncology Review (COR) COR provides collaborative, flexible central IRB review services for cancer research centers and their IRBs, offering an advanced level of partnership and service integration. COR's staff and IRB members include research professionals and clinicians with significant firsthand experience in contemporary oncology research and the associated unique human subject protection requirements. Powered by Schulman IRB's best-in-class customer service and technology, COR offers unmatched IRB expertise and efficiency in support of institutions at the cutting edge of oncology research.
About Schulman IRB Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its Provision Research Compliance Services division, offering comprehensive solutions to maximize the protection of human subjects and improve overall quality standards for clinical studies and data integrity. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).